Table: Taisho Pharmaceutical HD -Q1 group results
Aug 4 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2023 Jun 30, 2022 Mar 31, 2024
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 80.80 69.07 314.50
(+17.0 pct) (+8.1 pct) (+4.4 pct)
Operating 9.07 5.25 18.50
(+72.7 pct) (+96.3 pct) (-19.6 pct)
Recurring 11.13 9.25 22.00
(+20.3 pct) (+129.2 pct) (-27.7 pct)
Net 4.36 5.75 13.00
(-24.1 pct) (+387.6 pct) (-31.6 pct)
EPS 53.23 yen 70.16 yen 158.58 yen
EPS Diluted 53.15 yen 70.08 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10